Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Ligand Pharm (LGND)

Ligand Pharm (LGND)
105.54 x 6 105.85 x 2
Post-market by (Cboe BZX)
105.76 -0.71 (-0.67%) 04/23/25 [NASDAQ]
105.54 x 6 105.85 x 2
Post-market 105.76 unch (unch) 16:02 ET
Quote Overview for Wed, Apr 23rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
105.62
Day High
111.39
Open 109.51
Previous Close 106.47 106.47
Volume 171,300 171,300
Avg Vol 118,850 118,850
Stochastic %K 75.73% 75.73%
Weighted Alpha +33.12 +33.12
5-Day Change -1.04 (-0.97%) -1.04 (-0.97%)
52-Week Range 69.17 - 129.90 69.17 - 129.90
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,050,079
  • Shares Outstanding, K 19,255
  • Annual Sales, $ 167,130 K
  • Annual Income, $ -4,030 K
  • EBIT $ 10 M
  • EBITDA $ 45 M
  • 60-Month Beta 1.07
  • Price/Sales 12.07
  • Price/Cash Flow 65.23
  • Price/Book 2.38

Options Overview Details

View History
  • Implied Volatility 45.41% ( -0.20%)
  • Historical Volatility 41.68%
  • IV Percentile 71%
  • IV Rank 37.99%
  • IV High 65.30% on 04/08/25
  • IV Low 33.22% on 05/09/24
  • Put/Call Vol Ratio 4.00
  • Today's Volume 5
  • Volume Avg (30-Day) 7
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 392
  • Open Int (30-Day) 409

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.14
  • Number of Estimates 3
  • High Estimate 0.17
  • Low Estimate 0.10
  • Prior Year 0.80
  • Growth Rate Est. (year over year) -82.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
93.58 +13.02%
on 04/09/25
Period Open: 108.15
112.61 -6.08%
on 03/24/25
-2.39 (-2.21%)
since 03/21/25
3-Month
93.58 +13.02%
on 04/09/25
Period Open: 115.38
125.17 -15.51%
on 03/03/25
-9.62 (-8.34%)
since 01/23/25
52-Week
69.17 +52.91%
on 04/24/24
Period Open: 69.89
129.90 -18.58%
on 11/07/24
+35.87 (+51.32%)
since 04/23/24

Most Recent Stories

More News
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

LGND : 105.76 (-0.67%)
CHRO : 1.3700 (-11.61%)
Ligand to Participate in March Investor Conferences

LGND : 105.76 (-0.67%)
Ligand: Q4 Earnings Snapshot

Ligand: Q4 Earnings Snapshot

LGND : 105.76 (-0.67%)
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

LGND : 105.76 (-0.67%)
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

LGND : 105.76 (-0.67%)
Insider Sale: Director at $LGND (LGND) Sells 2,406 Shares

JOHN L LAMATTINA, a director at $LGND ($LGND), sold 2,406 shares of the company on 11-27-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 7.5% of their shares....

LGND : 105.76 (-0.67%)
Ligand: Q3 Earnings Snapshot

Ligand: Q3 Earnings Snapshot

LGND : 105.76 (-0.67%)
3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft Landing

Explore three small-cap stocks with 'Strong Buy' ratings that are poised for significant growth as economic conditions hint at a potential soft landing.

VKTX : 25.79 (+1.22%)
KNSA : 20.88 (+4.30%)
LGND : 105.76 (-0.67%)
VBR : 176.19 (+1.12%)
SCI : 80.34 (+1.09%)
Ligand: Q2 Earnings Snapshot

Ligand: Q2 Earnings Snapshot

LGND : 105.76 (-0.67%)
3 Magnificent Growth Stocks to Buy Hand Over Fist

Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.

AGEN : 2.85 (-0.70%)
LGND : 105.76 (-0.67%)
CURLF : 0.9065 (+2.14%)
CGC : 1.2400 (+5.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated...

See More

Key Turning Points

3rd Resistance Point 115.33
2nd Resistance Point 113.36
1st Resistance Point 109.56
Last Price 105.76
1st Support Level 103.79
2nd Support Level 101.82
3rd Support Level 98.02

See More

52-Week High 129.90
Fibonacci 61.8% 106.70
Last Price 105.76
Fibonacci 50% 99.53
Fibonacci 38.2% 92.37
52-Week Low 69.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective